Company

Applied Molecular Evolution

As of the edition of 20 October 2026, Applied Molecular Evolution runs 2 drugs; it is on route A at 2 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Went quiet1
Stopped1
Total2

Where it needs a new molecule

Route A at 2 targets, route B at 0 targets.

Three of its 2 rows, by target and route
TargetRoute
MS4A1 B-lymphocyte antigen CD20Route A
TNFSF13B Tumor necrosis factor ligand superfamily member 13BRoute A

All 2 rows on route A or B

In the product

2 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Blood and lymph: 2 trials led
  • Cancer: 2 trials led
  • Immune system: 2 trials led